Oral enzyme therapy for maple syrup urine disease ( MSUD ) suppresses plasma leucine levels in intermediate MSUD mice and healthy nonhuman primates

• Published in: Journal of inherited metabolic disease Vol. 46; no. 6; pp. 1089 - 1103
• Main Authors: Skvorak, Kristen, Liu, Joyce, Kruse, Nikki, Mehmood, Roasa, Das, Subhamoy, Jenne, Stephan, Chng, Chinping, Lao, U. Loi, Duan, Da, Asfaha, Jonathan, Du, Faye, Teadt, Leann, Sero, Antionette, Ching, Charlene, Riggins, James, Pope, Lianne, Yan, Ping, Mashiana, Harminder, Ismaili, Moulay Hicham Alaoui, McCluskie, Kerryn, Huisman, Gjalt, Silverman, Adam P.
• Format: Journal Article
• Language: English
• Published: Dordrecht Blackwell Publishing Ltd 01.11.2023
• Subjects: Amino acids; Directed evolution; Enzymes; Gastrointestinal tract; Intestine; Leucine; Maple syrup urine disease; Metabolism; Neurological complications; Neurotoxicity; Patients; Plasma; Proteins; Whey protein
• ISSN: 0141-8955; 1573-2665
• DOI: 10.1002/jimd.12662

Abstract Maple syrup urine disease (MSUD) is an inborn error of branched‐chain amino acid metabolism affecting several thousand individuals worldwide. MSUD patients have elevated levels of plasma leucine and its metabolic product α‐ketoisocaproate (KIC), which can lead to severe neurotoxicity, coma, and death. Patients must maintain a strict diet of protein restriction and medical formula, and periods of noncompliance or illness can lead to acute metabolic decompensation or cumulative neurological impairment. Given the lack of therapeutic options for MSUD patients, we sought to develop an oral enzyme therapy that can degrade leucine within the gastrointestinal tract prior to its systemic absorption and thus enable patients to maintain acceptable plasma leucine levels while broadening their access to natural protein. We identified a highly active leucine decarboxylase enzyme from Planctomycetaceae bacterium and used directed evolution to engineer the enzyme for stability to gastric and intestinal conditions. Following high‐throughput screening of over 12 000 enzyme variants over 9 iterative rounds of evolution, we identified a lead variant, LDCv10, which retains activity following simulated gastric or intestinal conditions in vitro. In intermediate MSUD mice or healthy nonhuman primates given a whey protein meal, oral treatment with LDCv10 suppressed the spike in plasma leucine and KIC and reduced the leucine area under the curve in a dose‐dependent manner. Reduction in plasma leucine correlated with decreased brain leucine levels following oral LDCv10 treatment. Collectively, these data support further development of LDCv10 as a potential new therapy for MSUD patients.